SRRK · Scholar Rock Holding
AI read · Good for SRRK
The AI's read
That gives Scholar Rock another route through the last U.S. production hurdle. The company says its second site has more vials available than Catalent's site, and FDA review of the second site's data is progressing. Approval has not happened, and the FDA's classification after a Catalent inspection is still pending. The added site and launch preparation support a positive read despite those remaining steps.